MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH
- Address
- lock Available on a paid plan
Rheumatoid Arthritis
The site focuses on rheumatoid arthritis, exploring new treatment options and comparing existing biologic and small‑molecule therapies to improve disease control.
- Long‑term safety of bimekizumab and upadacitinib
- Head‑to‑head efficacy of abatacept versus adalimumab
- Impact of novel TNFR1 inhibitor SAR441566
Investigators at MVZ Rheumatologie und Autoimmunmedizin Hamburg collaborate with pharmaceutical partners to bring innovative options to patients in Hamburg.
Psoriatic Arthritis
Research at the center includes extensive work on psoriatic arthritis, aiming to assess the effectiveness of emerging IL‑17 and JAK inhibitors as well as combination strategies.
- Evaluation of bimekizumab and risankizumab in biologic‑naïve patients
- Dose‑finding studies of sonelokimab and zasocitinib
- Comparative trials of deucravacitinib versus placebo
The program supports patients with active disease who have not responded adequately to conventional DMARDs.
Sjögren’s Syndrome
The facility conducts dedicated trials on Sjögren’s syndrome, targeting both systemic disease activity and patient‑reported symptom burden.
- Phase 2 evaluation of HZN‑1116 on systemic manifestations
- Assessment of efgartigimod PH20 and abiprubart for symptom relief
- Investigation of dazodalibep’s effect on ESSDAI scores
These studies aim to expand therapeutic choices for individuals suffering from dry‑eye and glandular dysfunction.
Axial Spondyloarthritis
Investigations into axial spondyloarthritis seek to determine long‑term safety of IL‑17 blockade and novel oral agents.
- Extended safety monitoring of bimekizumab in active disease
- Phase 2 trial of tulisokibart assessing ASAS 40 response
- Exploration of JNJ‑88545223 efficacy in radiographic disease
The research contributes to improved management of spinal inflammation and functional limitation.
Osteoarthritis & Metabolic Health
The center addresses osteoarthritis and related metabolic conditions, testing agents that may reduce joint pain while influencing body weight.
- Orforglipron study measuring WOMAC pain and weight change
- Eloralintide trial focusing on knee pain in overweight participants
- Evaluation of lifestyle‑linked outcomes alongside pharmacotherapy
Findings aim to provide integrated solutions for patients with joint degeneration and obesity.
Cardiovascular & Lipoprotein(a) Research
Trials at the site include investigation of cardiovascular risk in patients with elevated lipoprotein(a).
- Muvalaplin study assessing major adverse cardiovascular events
- Exploratory analysis of ASCVD prevention strategies
- Safety profiling of novel antibodies targeting Lp(a)
Results are expected to inform prevention approaches for high‑risk individuals.
Early Alzheimer’s Disease
A focused program evaluates disease‑modifying candidates for early symptomatic Alzheimer’s disease.
- Trontinemab trial measuring clinical progression at 72 weeks
- Biomarker assessments to track cognitive decline
- Safety monitoring in participants with mild cognitive impairment
The work supports the search for therapies that could slow or halt disease advancement.
COVID‑19 Prevention Studies
The institution participates in prophylactic research against COVID‑19, evaluating novel monoclonal antibodies.
- AZD3152 and EVUSHELD comparison for symptomatic infection prevention
- Safety cohort assessing AZD5156 tolerability
- Variant‑specific efficacy analyses
These investigations aim to protect vulnerable patients, including those with rheumatic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG6trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 53 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 4 | Unknown | 2016-05-10 | 2023-11-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.